A major exchange-traded fund provider is going deep on two popular plays: megacap tech and weight loss drug stocks. In health care, Roundhill Investments is getting ready to launch a fund that focuses on the companies behind GLP-1 drugs. Dave Mazza, the firm’s chief strategy officer, expects to have more information on the fund’s debut
“Long term, I’m still very bullish. But near term I just worry that everybody is coming into the year feeling too good,” the Neuberger Berman senior portfolio manager told CNBC’s “Fast Money” on Tuesday. On the year’s first day of trading, the tech-heavy Nasdaq fell 1.6% percent, the S&P 500 fell 0.6%, and the Dow
Socially responsible investors are optimistic heading into the new year. Sustainability-focused funds have seen outflows in all three completed quarters of this year, according to Morningstar. That comes as higher energy costs and the politicization of ESG investing frameworks weighed on traders. (The acronym is short for environmental, social and corporate governance.) However, ESG-minded money